Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
  • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
  • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P19/00—Preparation of compounds containing saccharide radicals
  • C12P19/26—Preparation of nitrogen-containing carbohydrates
  • C12P19/28—N-glycosides
  • C12P19/30—Nucleotides
  • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Definitions

• nucleotides modified for the synthesis of nucleic acids a kit containing such nucleotides and their use for the production of synthetic genes or nucleic acid sequences
• the present invention relates to the field of synthesis of functionalized copolymers of biological interest. It relates more particularly to nucleotides necessary for the synthesis of nucleic acids, in particular nucleic acids of great length, a kit containing such nucleotides and their use for the production of genes or synthetic nucleic acid sequences.
• each nudeotide to be added is protected at the level of the 5'-OH group so as to avoid an uncontrolled polymerization of several nucleotides of the same type.
• the protection of the 5'-OH group is carried out by a trityl group.
• the bases carried by the nucleotides can also be protected.
• the protection used involves an isobutyryl group (Reddy et al., 1997, Nucleosides & Nucleotides 16: 1589). After each incorporation of new nucleotides, the 5'-OH group of the last nudeotide of the chain undergoes a deprotection reaction in order to make it available for the next polymerization step.
• the nitrogenous bases carried by the nucleotides composing the nucleic acid they are deprotected only after completion of the complete polymerization.
• the polymerizing enzyme is directly added to natural nucleotides (Deng et al 1983, Meth Enzymol 100: 96). From an initial nucleic acid fragment called primer, the polymerization enzyme as well as nucleotides of the same type are added. The polymerization reaction is then initiated, the nucleic acid grows sequentially by repeating these phosphodiester bonding steps, until said polymerization is stopped by a physical or chemical method.
• nucleic acid fragments having a desired sequence results in uncontrolled polymerization resulting in a very heterogeneous mixture of nucleic acid molecules. Indeed nothing prevents the addition of several nucleotides of the same type after a first addition. In practice such a synthetic method is found to be unusable for the synthesis of nucleic acid fragments having a desired sequence.
• protected nucleotides makes it possible to a certain extent to solve this phenomenon of uncontrolled polymerization.
• the protected nucleotides allow the synthesis to be stopped by totally or partially preventing the creation of phosphodiester bonds subsequent to that desired.
• Nucleotides are the "monomers" used for the synthesis of nucleic acids. Their chemical properties as well as their capacity to react or not are guarantors of the smooth course of the desired synthesis. In order to be able to synthesize a nucleic acid fragment having the desired sequence, it is important to be able to polymerize the nucleotides one by one in the desired order. This polymerization is equivalent to the addition of nucleotides one after the other in an order that must be strictly observed, it must be ensured that several nucleotides comprising the same nitrogen base and introduced at the same time do not react in a chain, causing the uncontrolled growth of the oligomeric chain and thereby obtaining an erroneous sequence of nucleic acid.
• modified nucleotides with some structural modifications to the natural nucleotides, which gives them certain advantages when used for the synthesis of nucleic acids. They are generally obtained by chemical or enzymatic modifications of the nucleotides naturally present in the cells. Some modified nucleotides are said to be protected because they contain chemical groups preventing the modification of a chemical function to be preserved during other reactions. The protective groups may be arranged at different points of the nucleotide molecule. A particular class of protected nucleotides has a terminating function of the polymerization reaction. The role of these "chain terminator" nucleotides is to prevent excessive and unwanted polymerization of the nucleotides introduced into the reaction medium.
• a terminator nucleotide When a terminator nucleotide is incorporated into a nucleic acid molecule, hinders the subsequent polymerization of another nucleotide. Thus, only one nucleotide can be added to each nucleic acid molecule during the elongation step. Even if the different nucleotides, which make up the nucleic acid fragment to be synthesized, are introduced sequentially, it is necessary to use "terminator" nucleotides to avoid undesirable repetition phenomena.
• terminal nucleotides guarantees the reliability and reproducibility of nucleic acid synthesis methods, whether chemical or enzymatic. They can have a great influence on the synthesis performance of a given method.
• Protected nucleotides used for chemical synthesis of nucleic acids include 5'-OH position by a covalent bond to a DMT protective group (4.4, dimethoxytrityl) and the 3'-OH position a phosphoramidite group acting as catalyst of the nucleotide polymerization reaction with each other. These nucleotides comprising the DMT and phosphoramidite groups are called protected phosphoramidite nucleotides. Protection against uncontrolled polymerization is provided by the DMT protecting the 5'-OH.
• tritylation intervenes in order to remove the DMT group and obtain a 5'-OH group available for reacting with the nucleotide to be inserted. It is particularly important to have the most effective deprotection reaction possible in order to allow the addition of the next nucleotide in all cases.
• Protected phosphoramidite nucleotides are exclusively used in the chemical synthesis of nucleic acids. Their "terminator" function is in fact ensured by the DMT group linked to 5'-OH. The chemical synthesis taking place in the 3 'to 5' direction, the existence of a 5'-OH protecting DMT group makes it possible to avoid any excessive polymerization until the next step of deprotection.
• Terminator nucleotides have also been developed for so-called second generation sequencing methods. However, in addition to being totally unsuited to nucleic acid synthesis, terminator nucleotides used for sequencing have a number of crippling limitations.
• the main limitation is their ability to be used by elongation enzymes.
• the fluorescent markers linked to the terminating nucleotides for sequencing have a large size.
• the elongation enzymes have extremely little space within their active site and are therefore unlikely to be able to accept, in order to polymerize them, terminating nucleotides bearing imposing fluorescent groups, such as groups containing rings. aromatic conjugates.
• the modified nucleotides used for sequencing must have intact properties of pairing with their complementary nucleotides. Modified nucleotides should retain these essential interaction properties for their use.
• the nitrogenous bases that constitute the modified nucleotides for sequencing are analogs of natural nitrogen bases such as adenine, guanine, thymine, uracil and cytosine, and therefore do not have the same chemical structure: certain atoms are substituted by others and some groupings are added or deleted. These unnatural nitrogen bases can have many drawbacks, such as, for example, not being recognized by living organisms.
• the terminating nucleotides are deprotected to allow the addition of the next nucleotide.
• the deprotection step involves a physical or chemical means for removing the group responsible for the terminator function.
• the other functional groups associated with the modified nucleotide are deleted during similar deprotection steps. Must therefore generally several deprotection steps during the various sequencing processes to be able to proceed to the determination of the next nucleotide.
• These different steps of deprotection accumulate and multiply the use of powerful reagents or extreme physical conditions favoring the degradation of the various species present in the reaction medium and in particular the degradation of nucleic acids.
• a large number of deprotection steps considerably reduces the speed of the process and its performance.
• the existing modified nucleotides do not meet the expectations of enzymatic synthesis methods. Their poor use by the elongation enzymes, the placement of the different functional groups, the systematic use of modified nitrogen bases, the obligation of conservation of the interactions with the complementary nucleotides, the numerous stages of deprotection and the presence of residual scars, prohibit the use of these nucleotides for the enzymatic synthesis of nucleic acid.
• a first object of the invention is to provide modified nucleotides suitable for enzymatic synthesis of nucleic acids. Another object of the invention is to provide natural nucleotides modified by different functional groups to make them compatible with their use during a process of nucleic acid synthesis. Another object of the invention is to provide modified nucleotides for synthesizing nucleic acids of great length, that is to say of at least several hundreds or thousands of nucleotides, and more particularly according to the method described in FIG. patent application of the same applicant not yet published FR 14-53455.
• the present invention provides a modified nucleotide for the enzymatic synthesis of nucleic acids, such as long-chain nucleic acids, comprising a "natural" nitrogen base or a natural nitrogen-base analog, a carbohydrate.
• the modifying group is then a protective group
• R comprising at least one functional terminal group (which may also be called effector group).
• the modifying group is advantageously not a group of large size, such as a group comprising conjugated aromatic rings, in particular to allow access of the enzyme to the reaction site.
• the nucleotide according to the invention may be a mono-, di- or triphosphate, ie where the phosphate group (s) is free, that is to say unmodified.
• the nucleotide according to the invention is in the form of one of the following formulas (I), (III) or (IV): (Formula I)
• (PP) PO represents a mono-, di- or iriphosphate group
• M is a group covalently bound to Q and to Z, M being selected from alkyl, alkenyl, alkyne, aryl, alkylaryl, heteroaryl, acyl, alkyloxy, alkylamino, alkoxyamino, amido, alkylimido, alkenylimido, arylimido, fluoroalkyl, alkylphosphate, alkylthio, thioacyl, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, alkylammonium, alkylsulfonium, alkylsilyl, alkylcarbonyl, alkylcarbonyl, alkyl carbanyl, alkylcarbamoyl or alkyl hydroxyiamino,
• Q is a functional group, or end effector, of the R or R 'group, G being chosen from biotin, a protein, a defined sequence polynucleotide, a carbohydrate, an antigen, a hormone, a neurotransmitter, a glycoside such as digoxin, a sulphided radical, in particular carrying a thiol function such as glutathione, or a bidentate ligand such as catechol,
• R and R ' may be present independently or simultaneously, and when R and R' are present simultaneously:
• the groups M can be identical or different
• the groups Q may be identical or different.
• base represents a "natural" nitrogen base selected from adenine, thymine, cytosine, guanine or turacil or a natural nitrogen-base analogue, except for thymine when R 'is present and Q includes biotin.
• T when it is not hydrogen, as well as R and R 'constitute chain ending groups of the elongation step of a nucleic acid synthesis process.
• radical or cleavable group is meant a radical or a group covalently bonded to the oxygen in the 3 'or 2' position of the molecule of rlbose or 3 'position of the deoxyribose molecule, or to an atom of the nitrogen base, said bond being capable of being broken by chemical or photochemical means.
• the breakdown of all the bonds of the radicals or cleavable groups T and Z of the nucleotide molecule according to the invention is carried out integrally and simultaneously, that is to say during the same step of "deprotection", in particular by the application of the same condition or by the joint action of the same reagent.
• This suppression of the modifying groups is preferably total to result in the generation of nucleotide free of any modifying group, that is to say identical to a natural nucleotide (to the structure of the nitrogen base near).
• the groups R and R ' are groups advantageously providing its chain termination of the elongation step of a nucleic acid synthesis process.
• These groups R and R ' may possess properties, by means of the functional group Q placed at the free end of R and R', of attachment to another molecule, different from a nucleic acid, for example a molecule present on a support.
• the modified nucleotides used can interact with solid supports.
• These solid supports comprise on their surface molecules, proteins or chemical functions compatible with the modifying groups of the present nucleotides. This functionality of the modified nucleotides is then essential for the smooth running of the nucleic acid synthesis process.
• the modified nucleotides comprise a group which enables them to associate with a solid support in order to be purified, for example by forming, with the molecules present on the surface of a solid support, complex association with very low dissociation constant, in particular less than 1 0 "6 mol / L.
• the nucleotide according to the invention has a dual advantage, namely the presence of a group for the purification and destruction capacity of the same group simultaneously with the other modifying groups on the same nucleotide.
• the modifying group R is carried by the nitrogenous base and forms one of the following structures (V):
• V a Adenine-based structure (V a ) Thymine-based structure (V t )
• “Sugar” represents the bond between said nitrogen base and the ribose or deoxyribose molecule of the nucleotide molecule
• Z 1 and Z 2 are cleavable groups Z, identical or different,
• the groups Z, M and Q have the meanings described previously.
• the nucleotides are modified by groups borne by the atoms of the nitrogenous bases usually involved in the Watson-Crick pairing mechanisms, that is to say carried by the nitrogen atoms of the amino functions normally involved in complementary nucleotide pairing.
• the attachment of the different modifying groups to the constituent atoms of the nitrogenous bases is always carried out via the groups Z, of ciivable type, by a covalent bond type.
• a preferred embodiment of the present invention consists in linking the modifying group to the primary amine group 6-NH 2 (structure V a ).
• another preferred embodiment of the present invention is to bind the modifying group to the secondary amine group 3-NH (structure V t ).
• Another preferred embodiment of the present invention consists in linking the modifying group to the primary amine group 4-NH 2 (structure Vc ).
• another preferred embodiment of the invention consists in linking the modifying group to the secondary amine group 3-NH (structure V u ).
• another preferred embodiment of the present invention is to bind the modifying group to one or both of the amino groups, a secondary one, and a other primary 2-NH 2 , by means of ciivables groups (Structure V g ).
• a ring preferably consisting of 6 atoms, may occur between its different separator subgroups. This cycle possibly leads to a stabilization of the structure of the modifying groups.
• the modifying group is carried by the nitrogen base
• the 3 ⁇ and / or 2 ⁇ sites of the nucleotides are free, favoring their use as substrates for the eiongation enzymes during nucleic acid synthesis. Intermolecular hydrogen bonds can take place.
• the modifier R group carried by the nitrogenous base can form one of the following structures (VI):
• Vl a Adenine-based structure (Vl a ) Thymine-based structure (Vl t )
• “Sugar” represents the bond between said nitrogen base and the ribose or deoxyribose molecule of the nucleotide molecule
• X 1 and X 2 which are identical or different, represent nitrogen, oxygen or sulfur atoms borne by M and capable of forming with said nitrogen bases of the modified nucleotide intramolecular hydrogen bonds (these hydrogen bonds are then similar to hydrogen bonds intermolecular observed during classical pairings between complementary nucleotides).
• This configuration enhances the stability of the modified nucleotides. It also influences the compactness of the modifying groups and allows their use by elongation enzymes usually dependent on the presence of a template strand.
• a preferred embodiment of réaiisation of the present invention to bind the modifier group to the primary amine 6-NH 2 (VI structure).
• the X group present promotes the creation of an intramoiecular hydrogen bond with the nitrogen atom 1 of the purine ring. Thus the presence of a complementary thymine is mimed.
• a preferred embodiment of the present invention consists in linking the modifying group to the secondary amine group 3-NH (structure VI t ).
• the present SUPERe group promotes the creation of an intramoiecular hydrogen bond with the oxygen atom at the 4-position of the pyrimidine ring.
• a complementary adenine is mimed.
• a preferred embodiment of the present invention consists in linking the modifying group to the two amino groups, the first secondary 1 -NH and the second primary 2-NH 2 (structure VI g ) by via cleavable groups Z 1 and Z 2 .
• the X- ⁇ group present promotes the creation of an intramolecular hydrogen bond with the oxygen atom at 6 of the purine ring.
• the presence of a complementary cytosine is mimed.
• a preferred embodiment of the invention consists in linking the modifying group to the secondary amine group 3-NH (structure Vi u ).
• the X 1 group present promotes the creation of a hydrogen bond with oxygen at the 4-position of the pyrimidine ring.
• the presence of a complementary adémine is mimed.
• modified nucleotides according to the present invention do not necessarily have the function of being associated with a possible complementary nucleotide carried by any template strand.
• modified nucleotides that are the subject of the present invention for the generation of nucleic acids, the latter are not necessarily intended to be incorporated by additional interaction with a possible matrix strand.
• the modified nucleotides object of the present invention possess characteristics enabling them to lose their modifying groups during specific steps. At the end of the loss of all of their modifying groups, the nucleotides of the present invention thus transformed then cover their capacity to mate with complementary nucleotides carried by template strands.
• the nudeotide according to the invention can then be used as a substrate for polymerases normally dependent on the presence of a complementary nucleic acid strand of the strand being synthesized, even in the absence of a complementary strand. .
• the functional terminal radical Q of the group R or R ' is preferably capable of allowing, during the nucleic acid synthesis, the attachment of said nudeotide to a solid support, via a molecule other than an acid.
• nucleic acid such as a protein, attached to the surface of said support, and more particularly capable of interacting with molecules other than a nucleic acid, according to one or other of the following pairs of interactions: antigen / antibody, hormone / receptor, biotin / (strept) avidin, neurotransmitter / receptor, polymerase / promoter, digoxin / antidigoxtne, carbohydrate / lectin, sulphide radical / metal such as gold, glutathione / glutathione S-transferase, or bidentate / oxide ligand metallic.
• the metal oxides may be, for example, Ti0 2, Zr0 2> Ce0 2, Fe 3 0 4, Ga 2 0 3, ln 2 0 3, Cr 2 0 3, Al 2 0 3, ZnO, CuO, Cu 2 0 3 , Mn 3 O 4 , Mn 2 O 3 , V 2 O 3 MO0 2 .
• the bidentate ligands may be catechol, hydroxamate or hydroxycarboxylate.
• the radical T is said to be "blocker” in that it protects the 3'-hydroxyl group or the 2'-hydroxyl group of the carbohydrate against any additional nucleotide addition.
• T and Z, or ZZ 2 are cleavable, during the synthesis of nucleic acid, by irradiation of said nudeotide by means of electromagnetic radiation of wavelength between 10 ⁇ 3 and 10 "11 meters, especially by exposure to ultraviolet radiation.
• the present invention also relates to the use of nucleotides, as described above, in a method for producing genes, synthetic nucleic acid sequences, DNA, RNA or nucleic acid polymers, in particular according to an enzymatic synthesis process.
• nucleotide in a polynucleotide chain previously immobilized on a solid support, more particularly when the polynucleotide chain is attached by its 5 'end and the incorporation of said nucleotide is carried out by the 3' end of the polynucleotide chain.
• nucleotides according to the invention are in free form, in association with a counterion if necessary. Although having the ability to bind to a solid support, these nucleotides are free of any support at the time of their incorporation into the polynucleotide chain. Their chemical structure is therefore not linked to any solid support.
• modified nucleotides are particularly important for their use in the process described in the unpublished patent application FR 14-53455 because the nucleotides are added to fragments of nucleic acids which are themselves immobilized. These fragments are released and, thanks to the effector group of newly incorporated nucleotides, are then fixed by the opposite end to a second solid support. It is therefore the complete nucleic acid chains, or polynucleotides, of desired sequence which are fixed to a solid support and not the nucleotides according to the invention, used to construct the polynucleotides.
• the present invention also relates to a kit comprising at least one modified nucleotide according to the invention, more particularly said kit may comprise various modified nucleotides, an eniongation enzyme and a solid support capable of binding at least one of said nucleotides.
• Figure 1 shows the different general structures of the modified nucleotides object of the present invention
• FIG. 1 shows the particular structures of the modified nucleotides of formula (V);
• Figure 3 presents its formulas of natural nitrogen bases adenine, thymine, cytosine and guanine;
• Figure 4 shows examples of modifying groups capable of intramolecular hydrogen bonding interactions of formula (VI);
• Figure 5 schematizes the synthesis of the compound NH 2 -dTTP-NitroB-Biot
• Figure 6 schematizes the synthesis of the compound NH 2 -dGTP-NitroN-Biot
• Figure 7 schematizes the synthesis of FA-Biot-dNTP compounds
• Figure 8 schematizes the synthesis of the dATP-NitroB-Biot compound:
• Figure 9 schematizes the synthesis of the compound dCTP-NitroB-Biot
• Figure 10 shows an example of deprotection of the polymerized NH 2 -dT-NitroB-Biot compound. ;
• Figure 11 shows an example of deprotection of the polymerized NH 2 -dG-NitroB-Biot compound. ;
• Figure 12 shows an example of deprotection of polymerized FA-Biot-dNTP compound
• Figure 13 shows an example of photo-cleavage deprotection of the polymerized dA-NitroB-Biot compound
• Figure 14 shows an example of deprotection by chemical cleavage of the polymerized dC-NitroB-Biot compound
• Figure 15 shows an example of modified nucioteotide according to the present invention, the Q group being a catechol;
• Figure 16 schematizes the synthesis of the FA-Cat-dNTP compound.
• Step A2 To a solution of 2,237 mmol of dTTP-A1 product, 2.1 g of triphenylphosphine and 1.3 g of N-hydroxyphthalimide in 50 mL of tetrahydrofuran is added 1.75 mL of N-N'-diisopropyl azodicarboxyldate. 0 ° C. After warming to room temperature overnight, the reaction product is treated with 0.3 mL of water and the solvent is evaporated in vacuo. Most of the impurities are removed by chromatography to give the product dTT-A2.
• Step A3 To one equivalent of dTT-A2 compound are added 10 equivalents of LiH in DMF at room temperature. The mixture reacts for 30 minutes. The reaction is continued by the addition of 3-amino-4- (bromomethyl) -5-nitrophenyl-biotin, and the mixture is stirred for several hours. The product dTT-A3 is obtained.
• Step A4 The dTTP-A3 compound is resuspended in methanol and treated with aqueous concentrated hydrochloric acid. The solution is cooled to -20 ° C overnight resulting in the product dTTP-A4.
• Step A5 To 425 mg of nucleoside 5'-OH analogue dTTP-A4 solubilized in 2 mL of pyridine and 1.7 mL of dioxane is added a solution of 130 mg of 2-chloro-4H-1,2,3-benzodioxaphosphorin -4-one in 1.3 mL of dioxane. The mixture is left at ambient temperature for 20 minutes.
• Step A6 0.385 mL of cold methylhydrazine is added to 3.725 mmol of dTTP-A5 compound in anhydrous CH 2 Cl 2 at -5 ° C. After 10 min a precipitate of 2-dihydro-4-hydroxy-2-methyl-1-oxophthalizine is formed. The mixture is stirred for 1 h at room temperature. The precipitate is removed by filtration and washed with CH 2 Cl 2 . The filtrate is then concentrated under a rotary evaporator and purified by chromatography to give the product NH 2 -dTTP-NitroB-Biot.
• Step B1 To a stirred solution of 1. 845 mmol of 2'-deoxyguanine and 326 mg of imidazole in dry DMF is added 2.4 mmol of tert-butyldimethylsilyl chloride. The reaction is incubated with stirring at ambient temperature for 20 hours. The solvents are removed in vacuo and the residue is purified by chromatography to give the product dGTP-B1.
• Step B2 To a solution of 2,237 mmol of dGTP-B1 product, 2.1 g of triphenylphosphine and 1.3 g of N-hydroxyphthalimide in 50 mL of tetrahydrofuran is added 1.75 mL of N-N'-diisopropyl azodicarboxylate. 0 ° C. After warming to room temperature overnight, the reaction product is treated with 0.3 mL of water and the solvent is evaporated in vacuo. Most of the impurities are removed by chromatography, yielding the dGTP-B2 product.
• Step B3 3.785 mmol of dGTP-B2 compound are dried several times using 10 mL pyridine and evaporation under vacuum. The residue is dissolved in 12.5 mL of CH 2 Cl 2 . 9 mmol of diisopropylethylamine and 7.57 mmol of 6-amino-4,5- bis (iodooxy) -3-niironaphtha [en-1-yl 5-biotin are added. When the reaction is complete, the mixture is diluted in 100 mL of CH 2 Cl 2 , the organic phase is washed with 50 mL of sodium bicarbonate and 50 mL of water. It is then dried over sodium sulfate. The solvents are evaporated under vacuum and the product purified by chromatography to give dGTP-B3.
• Step B4 3.75 mmol of dGTP-B3 compound are dissolved in 20 mL of THF and treated with 1 M TBAF (tetra-n-butylammonium fluoride) in THF. The reaction is complete after about 2 hours with stirring. The mixture is extracted with CH 2 Cl 2 and purified by chromatography to give dGTP-B4.
• TBAF tetra-n-butylammonium fluoride
• Step B5 425 mg of analogous 5'-OH nucleoside are treated similarly to Step A5 of Example 1. The final mixture is filtered and purified by reverse HPLC to give a triphosphate compound, in this case dGTP-B5.
• Step B6 0.385 mL of cold methylhydrazine is added to 3.725 mmol of dGTP-B5 compound in anhydrous CH 2 Cl 2 at -5 ° C. After 10 min a precipitate of 1,2-dihydro-4-hydroxy-2-methyl-1-oxophthalizine is formed. The mixture is stirred for 1 h at room temperature. The precipitate is removed by filtration and washed with CH 2 C! 2 . The filtrate is then concentrated under a rotary evaporator and purified by chromatography to give the NH 2 -dGTP-NitroN-Biot product.
• Step C1 100 ⁇ l of 1M non-biotin nonanoic acid in DMF are mixed with 100 ⁇ l of 1 M carbonyidiimidazole in DMF. The imidazolide formation is carried out in 30 s at room temperature. Then 100 ⁇ l of 50 mM deoxyribonucleotides 5'-triphosphate in water are added to the mixture. The product is formed in 12 h room temperature, it is then precipitated with acetone and dissolved in water to be finally purified by chromatography to give the product FA-Biot-dNTP.
• Step D1 To 5 g of 2'-deoxyadenine solubilized in pyridine are added 2.2 ml of Et 3 N and 175 mg of DMAP then 5.25 g of DMTCi at room temperature overnight. 2.4 mL of Et 3 N and 1, 27 mL of MsC! are then added to the mixture. After 2 hours incubation at room temperature, the mixture is filtered and washed with ethyl acetate. The filtrate is concentrated and dissolved in 75 ml of ethanol to which is added 1 M NaOH. After refluxing for 1.5 h, the mixture is cooled to room temperature and 1 M HCl is added. The ethanol is evaporated by rotary evaporator and the residue is extracted with CH 2 Cl 2 . After purification on a column of silica gel, the product dATP-D1 is obtained.
• Step D2 To a stirred solution of 1. 845 mmol! of dATP-D1 and 326 mg of imidazole in anhydrous DMF are added 2.4 mmol of tert-butyldimethylsilyl chloride. The reaction is incubated with stirring at ambient temperature for 20 hours. The solvents are removed by applying vacuum and the residue is purified by chromatography to give the dATP-D2 product.
• Step D3 The dATP-D2 compound is resuspended in methanol and treated with aqueous concentrated hydrochloric acid. The solution is cooled to -20 ° C overnight resulting in dATP-D3 product.
• Step D4 A 425 mg of analogous 5'-OH nucleoside are similarly treated in step A5 of Example 1. The final mixture is filtered and purified by reverse HPLC to give a triphosphate compound, in this case dATP -D4.
• Step D5 3.1mol of the dATP-D4 compound in 200 ⁇ l of 0.1 M NaHCO 3 pH 8.0 are mixed with 3.4 pmol of 2,2-terbutyl-1- (2-nitro-4-biotin) phenyl) hexyl (2,5-dioxopyrrolidin-1-yl) carbonate in 200 ⁇ l of dimethylformamide. The reaction is conducted at room temperature overnight to give dATP-D5 (Olejnik et al., PNAS, 1995, Vol 92, 7590-7594).
• Step D6 3.75 mmol of the dATP-D5 compound are dissolved in 20 mL of THF and treated with 1 M TBAF (tetra-n-butylammonium fluoride) in THF. The reaction is complete after about 2 hours with stirring. The mixture is extracted with CH2Cl2 and purified by chromatography to give dATP-NitroB-Biot.
• TBAF tetra-n-butylammonium fluoride
• Step E1 To 5 g of 2'-deoxycytidine solubilized in pyridine are added 2.2 mL of Et 3 N and 175 mg of DMAP then 5.25 g of DMTCI at room temperature during the night. 2.4 ml of Et 3 N and 1, 27 ml of MsCl are then added to the mixture. After incubation for 2 h at room temperature, the mixture is filtered and washed with ethyl acetate. The filtrate is concentrated and dissolved in 75 mL of ethanol to which is added 1 M NaOH.
• Step E2 To a stirred solution of 1. 845 mmol of dCTP-E1 and 326 mg of imidazole in anhydrous DMF is added 2.4 mmol of tert-butyldimethylsilyl chloride. The reaction is incubated with stirring at ambient temperature for 20 hours. The solvents are removed by applying vacuum and the residue is purified by chromatography to give the product dCTP-E2.
• Step E3 dCTP-E2 is dissolved in absolute ethanol and cooled to 0 ° C. An equimolar solution of 2,2-terbutyl-1- (2-nitro-4-biotin) phenyl) propyl! phenyl carbonate in absolute ethanol is added taste to taste. The mixture is stirred at room temperature overnight. The solution is filtered, washed with water and extracted with CH 2 Cl 2 to give dCTP-E3.
• Step E4 The dCTP-E3 compound is resuspended in methanol and treated with aqueous concentrated hydrochloric acid. The solution is cooled to ⁇ 20 ° C overnight resulting in the product dCTP-E4.
• Step E5 A 425 mg of analogous 5'-OH nucleoside are treated similarly to Step A5 of Example 1. The final mixture is filtered and purified by reverse HPLC to give a triphosphate compound, in this case dCTP E5.
• Step E6 3.75 mmol of the dCTP-E5 compound are dissolved in 20 mL of THF and treated with 1 M T8AF (tetra-n-butylammonium fluoride) in THF. The reaction is complete after about 2 hours with stirring. The mixture is extracted with CH 2 Cl 2 and purified by chromatography to give dCTP-NitroB-Biot.
• T8AF tetra-n-butylammonium fluoride
• Step F1 100 ⁇ l of 1 M modifier catechol ester in DMF are mixed with 110 ⁇ l of 1 M dicyclohexylcarbodiimide (DCC) and 5 ⁇ l of 100% 4- (dimethylamino) pyridine in DMF. The mixture is incubated at 0 ° C for 5 min. 500 ⁇ of deoxyribonucleotide 5'-triphosphate 50 mM in DMF are then added to the mixture. The product is formed in 3 hours at room temperature. It is then precipitated with acetone and dissolved in water to be finally purified by chromatography to give the FA-Cat-dNTP product.
• DCC dicyclohexylcarbodiimide
• examples 7 to 1 1 illustrate embodiments of the deprotection of said nucleotide, that is to say the elimination of the group (s) modifier (s) (s).
• EXAMPLE 7 Deprotection of the NH 2 -dT-NitroB-Biot Polymer Nucleotides (FIG. 10) The cleavage of the different modifying groups is carried out simultaneously during the following process. 20 mM of NH 2 -dT-NitroB-Biot compound in aqueous solution are treated with a solution comprising 350 to 700 mM NaN0 2 and 1 M NaOAc pH 5.5. After 1 to 2 minutes of incubation at ambient temperature under UV light with a wavelength of 365 nm, the reaction is stopped by the addition of 1 M phosphate buffer pH 7.0 and the illumination is stopped. The product of the deprotection reaction is dT.
• the cleavage of the different modifying groups is carried out simultaneously during the following process: 20 mM of NH 2 -dG-NitroN-Biot compound in aqueous solution are treated with a solution comprising 350 to 700 mM NaN0 2 and 1 M NaOAc pH 5.5. After 1 to 2 minutes of incubation at ambient temperature under UV light with a wavelength of 365 nm, the reaction is stopped by the addition of 1 M phosphate buffer pH 7.0 and the illumination is stopped. The product of the deprotection reaction is dG.
• the cleavage of the modifying groups carried by the 3'-OH end is carried out by hydrolysis of the ester function with an aqueous ammonia solution, 1 to 100 mM, at ambient temperature for 1 h.
• the product obtained is of type dN.
• the cleavage of the modifying groups carried at the level of the nitrogenous base is carried out by photo-cleavage.
• the A-NitroB-Biot compound is exposed to a UV source of wavelength 300 to 370 nm at room temperature. The UV source is stopped after 30 to 300 seconds to give the product dA.
• the cleavage of the modifying groups carried at the level of the nitrogenous base is carried out by chemical cleavage.
• 0.01 mmol of dC-NitroB-Biot compound is dissolved in 0.1 ml of ethanol.
• a solution of 0.02 mmol of sodium tetrachloropalladate II dissolved in ethanol is added. Hydrogen gas is bubbled into the mixture with stirring for 20 min.
• the product obtained is dC.
• the modified nucleotides which are the subject of the present invention may advantageously be used to carry out the enzymatic synthesis of nucleic acids without the presence of template strands according to the method described in the patent application FR 14-53455.
• the enzyme chosen for carrying out the addition step of the modified nucleotides is the deoxynucleotidyl transferase terminal or commercially available TdT.
• the primer used to initiate the synthesis is given below:
• the modified nucleotides used are NH 2 -dTTP-NitroB-Biot prepared according to Example 1. They make it possible to add a T to the sequence No. 1 presented. It is expected that a single nucleotide will be added to each DNA fragment during each step of elongation, as described below.
• a glass plate carrying "capture" fragments having the following sequence: 5'-GTCCGCTTGGCT-3 'Seq No. 2
• This glass plate constitutes the bottom of a parallelipipedic reaction chamber with a volume of 50 ⁇ L.
• the synthesis starts with the addition of the following reagents in the reaction chamber: 50 U TdT, 1 M potassium cacodylate, 125 mM Tris-HCl, 0.05% (v / v) Triton X-100, mM CoCl2, pH 7.2. 100 ⁇ l of free NH2-dTTP-NitroB-Biot nucleotides and in solution with their counter ions are then added. The enzyme at 2 ⁇ is finally added to start the addition reaction. The total reaction volume is 50 ⁇ L. The mixture is incubated for 5 min at 37 ° C.
• the DNA fragments having incorporated the NH 2 -dTTP-NitroB-Biot protected nucleotide are then purified according to the following procedure.
• Commercial streptavidin-coated magnetic beads prepared according to the manufacturer's protocol are added to the 50 ⁇ L of the previous reaction mixture. After 1 h of incubation at room temperature, the magnetic beads are collected by means of a suitable magnet. The supernatant is then removed. The beads are then washed 3 times with the washing buffer: tris buffer pH 7.2 with 0.1% Tween-20.
• the magnetic beads to which the DNA fragments having incorporated the modified NH 2 -dTTP-NitroB-Biot nucleotides are resuspended in a solution comprising 350 to 700 mM NaN0 2 and 1 M NaOAc at pH 5.5.
• the mixture is incubated for 1 to 2 minutes at room temperature under UV exposure (365 nm).
• the reaction is stopped by adding 1 M phosphate buffer at pH 7.0 and stopping the illumination. This operation allows the "stall" of the DNA fragments of their supports (beads).
• the magnetic beads are collected thanks to a suitable magnet.
• the supernatant is recovered and analyzed by electrophoresis gel and ALDI-TOF MS spectrometer to verify the good incorporation of the base T at the 3 'end of the sequence No. 1 in more than 99% of cases.
• a new eiongation step can then be carried out if necessary according to the same protocol.
• modified nucleotides that are the subject of the present invention may advantageously be used to carry out the enzymatic synthesis of nucleic acids without the presence of template strands according to the process described in the patent application FR 14-53455.
• the enzyme chosen for carrying out the addition step of the modified nucleotides is the deoxynucleotidyl transferase terminal or commercially available TdT.
• the primer used to initiate the synthesis is given below:
• the modified nucleotides used are NH 2 -DGTP-NitroB-Biot prepared according to example 2. They allow to add a G to the sequence No. 1 presented, it is expected that a single nucleotide will be added to each fragment of DNA during each eiongation step, as described below.
• a glass plate having capture fragments having the following sequence: 5'-GTCCGCTTGGCT-3 'Seq No. 2
• This glass plate constitutes the bottom of a parallelipipedic reaction chamber with a volume of 50 ⁇ .
• the synthesis starts with the addition of the following reagents in the reaction chamber: 50 U TdT, 1 M potassium cacodylate, 125 mM Tris-HCl, 0.05% (v / v) Triton X-100, 5 mM CoCl2, pH 7.2. 100 ⁇ l of free NH2-dGTP-NitroB-Biot nucleotides and in solution with their counter ions are then added. The enzyme at 2 ⁇ is finally added to start the addition reaction. The total reaction volume is 50 ⁇ L. The mixture is incubated for 5 min at 37 ° C.
• the DNA fragments having incorporated the NH2-dGTP-NitroB-Biot protected nucleotide are then purified according to the following procedure.
• Commercial streptavidin-coated magnetic beads prepared according to the manufacturer's protocol are added to the 50 ⁇ L of the reaction mixture! previous. After 1 h of incubation at room temperature, the magnetic beads are collected by means of a suitable magnet. The supernatant is then removed. The beads are then washed 3 times with the washing buffer solution: tris buffer pH 7.2 with 0.1% Tween-20.
• the magnetic DNAs to which the DNA fragments having incorporated the NH 2 -dGTP-NitroB-Biot modified nucleotides were resuspended in a solution comprising 350 to 700 mM NaNO.sub.2 and 1 M NaOAc at pH 5.5. The mixture is incubated for 1 to 2 min at room temperature under UV exposure (365 nm). The reaction is stopped by adding 1 M phosphate buffer pH 7.0 and stopping the illumination. This operation allows the "stall" of the DNA fragments of their supports (beads).
• the magnetic beads are collected thanks to a suitable magnet.
• the supernatant is recovered and analyzed by electrophoresis gel and MALDI-TOF S spectrometer to verify the good incorporation of the base T at the 3 'end of the sequence No. 1 in more than 99% of cases.
• a new eiongation step can then be performed according to the same protocol.
• the modified nucleotides that are the subject of the present invention improve the performance of nucleic acid synthesis processes, in particular by enabling the synthesis of very long nucleic acids of very high quality.
• These nucleotides can be used for the production, on a larger or smaller scale, of synthetic genes or nucleic acid sequences.
• These modified nucleotides are particularly intended for the synthesis of nucleic acids such as DNA or RNA for purposes of research, development or industrialization in the field of biotechnology or more generally in the broad field of biology.

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=52102784

Family Applications (2)

Family Applications After (1)

Country Status (10)

Families Citing this family (23)

Family Cites Families (43)

• 2014
  • 2014-09-02 FR FR1458194A patent/FR3025201B1/fr active Active
• 2015
  • 2015-09-01 US US15/507,853 patent/US11059849B2/en active Active
  • 2015-09-01 AU AU2015310781A patent/AU2015310781B2/en active Active
  • 2015-09-01 KR KR1020177009072A patent/KR20170049565A/ko not_active Application Discontinuation
  • 2015-09-01 EP EP15766907.8A patent/EP3189066A1/fr not_active Withdrawn
  • 2015-09-01 CA CA3057218A patent/CA3057218C/fr active Active
  • 2015-09-01 CA CA2958135A patent/CA2958135C/fr active Active
  • 2015-09-01 EP EP18153938.8A patent/EP3339314B1/fr active Active
  • 2015-09-01 CN CN201580046871.XA patent/CN107074903B/zh active Active
  • 2015-09-01 JP JP2017510607A patent/JP6839650B2/ja active Active
  • 2015-09-01 WO PCT/FR2015/052310 patent/WO2016034807A1/fr active Application Filing
• 2017
  • 2017-02-09 IL IL250539A patent/IL250539B/en active IP Right Grant

Also Published As

Similar Documents

Legal Events